Charles River Laboratories International Aktie
WKN: 939391 / ISIN: US1598641074
22.03.2006 17:00:00
|
Charles River Laboratories Signs Licensing Agreement with Washington University
William Barbo, Charles River Laboratories Corporate VicePresident, Research Model Services, said, "Charles River is pleased tojoin Washington University in this licensing agreement. Utilizing theinnovative MNV technology developed in the laboratories of Dr. SkipVirgin at the university, Charles River will continue to be in theforefront of laboratory animal diagnostic testing."
Jon Kratochvil, Business Development Director at WashingtonUniversity, said, "I am pleased that Charles River Laboratories is thefirst company to recognize the potential of Dr. Virgin's novel murinenorovirus discovery. Based on Charles River's business model, Ibelieve that Charles River is an excellent company to commercializethis technology, and validate the importance and prevalence of thisnorovirus in mouse colonies and ensuing research projects."
About Charles River Laboratories
Charles River Laboratories, based in Wilmington, Massachusetts,U.S., is a global provider of solutions that advance the drugdiscovery and development process. Our leading-edge products andservices are designed to enable our clients to bring drugs to marketfaster and more efficiently. Backed by our rigorous, best-in-classprocedures and our proven data collection, analysis and reportingcapabilities, our products and services are organized into threecategories spanning every step of the drug development pipeline:Research Models and Services, Preclinical Services, and ClinicalServices. Charles River's customer base includes all of the majorpharmaceutical companies and many biotechnology companies, governmentagencies and leading hospitals and academic institutions. CharlesRiver's 8,400 employees serve clients in more than 50 countries. Formore information on Charles River, visit our website atwww.criver.com.
About Washington University
Washington University School of Medicine's full-time and volunteerfaculty physicians also are the medical staff of Barnes-Jewish and St.Louis Children's hospitals. The School of Medicine is one of theleading medical research, teaching and patient care institutions inthe nation, currently ranked third in the nation by U.S. News & WorldReport and is ranked fourth among U.S. medicals schools in fundingfrom the National Institutes of Health. Through its affiliations withBarnes-Jewish and St. Louis Children's hospitals, the School ofMedicine is linked to BJC HealthCare.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Charles River Laboratories International Inc.mehr Nachrichten
31.03.25 |
Handel in New York: S&P 500 verbucht zum Ende des Montagshandels Gewinne (finanzen.at) | |
31.03.25 |
S&P 500-Handel aktuell: Das macht der S&P 500 nachmittags (finanzen.at) | |
31.03.25 |
Börse New York in Rot: So performt der S&P 500 am Montagmittag (finanzen.at) | |
31.03.25 |
S&P 500-Papier Charles River Laboratories International-Aktie: So viel hätten Anleger an einem Charles River Laboratories International-Investment von vor 10 Jahren verdient (finanzen.at) | |
24.03.25 |
S&P 500-Titel Charles River Laboratories International-Aktie: So viel hätten Anleger mit einem Investment in Charles River Laboratories International von vor 5 Jahren verdient (finanzen.at) | |
20.03.25 |
Schwacher Handel: S&P 500 präsentiert sich zum Handelsende leichter (finanzen.at) | |
20.03.25 |
Anleger in New York halten sich zurück: So entwickelt sich der S&P 500 nachmittags (finanzen.at) | |
20.03.25 |
Verluste in New York: So performt der S&P 500 am Mittag (finanzen.at) |
Analysen zu Charles River Laboratories International Inc.mehr Analysen
Aktien in diesem Artikel
Charles River Laboratories International Inc. | 124,50 | -6,18% |
|